Despite pressure from the administration, a rough start to the year, biotech has seen a rebound this year. Our next guest is betting that that recovery will continue into 2026. So joining us now, Salivine Richtor.She is the lead US biotech analyst at Goldman Sachs Research. And Salivine, it's great to have you on the show. Welcome.>> Thank you for having me. What's interesting to me is that these names of these, you know, these stocks of these pharma companies that did inc this deal with the president just ...